Restoring the immune system to eradicate cancer

About Amphivena Therapeutics

Amphivena Therapeutics, Inc. is a privately held, clinical-stage, immuno-oncology company that is developing a novel platform of dual-action biologics that relieve immune suppression and drive T-cell activation and polarization to restore anti-cancer immunity in patients


Our science and platform target the suppressed immune system of cancer patients to restore anti-cancer immunity

The fundamental challenge in immuno-oncology is that a majority of patients do not respond to immunotherapies. Cancer patients exhibit tumor-induced immune suppression mediated by immune cell types such as myeloid derived suppressor cells (MDSC). T cell activating therapies can also trigger autoregulatory immune modulation, via MDSC recruitment.


Our proprietary platform is designed to potently and selectively deplete MDSC and to drive the activation and repolarization of T cells to relieve immune suppression and restore anti-cancer immunity in patients.

About our science


The AMPHIVENA ReSTORE™ platform provides dual-action biologics that relieve immune suppression and activate
T cell effector function in cancer patients


The platform can be engineered with additional solid tumor targeting modalities to add functionality such as directed tumor cell killing

About our platform


Our lead candidate, AMV564, is currently in clinical studies in both solid tumor and hematologic cancers


We are advancing additional bivalent, multi-target candidates through preclinical development

About our science

The Amphivena team has deep experience in the development of innovative therapeutic platforms and transformative medicines for improving patient lives

Meet the team
Join our team

Latest News

Press Release
November 9, 2020

South San Francisco, CA – November 9, 2020 — Today Amphivena presented updated clinical and translational data for the lead clinical candidate, AMV564, from the AMPHIVENA ReSTORETM (Relieve Suppression of T cells in Oncology and Reinvigorate Effectors) platform of bivalent T-cell engagers, in two poster presentations at the SITC 2020 Annual Meeting…

Press Release
June 23, 2020

South San Francisco, CA – May 29, 2020 — AMV564, a novel first-in-class agent that depletes MDSC and polarizes T cells, is being investigated in Ph1 clinical trials in advanced solid tumors and hematological cancers and is well tolerated with single-agent activity across both solid and heme malignancies…

Press Release
May 29, 2020

South San Francisco, CA – May 29, 2020 — Initial data from the Phase 1 dose escalation trial in 18 patients with advanced solid tumors shows AMV564 administered subcutaneously was well tolerated, with no dose-limiting toxicities…


Two Tower Place, Suite 1000
South San Francisco, CA 94080 USA
Phone: 650-499-3178


General Inquiries: